Insider · CIK 0001242110

BLATT LAWRENCE

Reports to the SEC for 2 companies · SOUTH SAN FRANCISCO, CA

sec.gov

Transactions

Companies

Filings

CIK

0001242110

Forms 4 and 5

Insider transactions

50 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-09	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+106K sh	—	—	105,840
2025-07-16	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+180K sh	—	—	179,800
2025-02-28	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+140K sh	—	—	140,103
2024-09-04	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+33.9K sh	—	—	33,920
2024-03-01	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+965K sh	—	—	965,435
2024-02-28	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+132K sh	—	—	132,352
2024-02-28	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+231K sh	—	—	230,999
2024-02-28	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+57.7K sh	—	—	57,749
2024-02-27	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−450K sh	—	—	0
2024-02-27	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−323K sh	—	—	0
2024-02-27	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)D Disposition to Issuer	Director, President and CEO	DDisposition to Issuer	−80.9K sh	—	—	0
2023-10-25	ALGSAligos Therapeutics, Inc.A Award	Director, President and CEO	AAward	+610K sh	$0.76	+$462K	1,847,575
2023-10-25	ALGSAligos Therapeutics, Inc. · Warrants (Right to Buy)A Award	Director, President and CEO	AAward	+305K sh	$0.13	+$38.1K	305,138
2023-09-08	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+150K sh	—	—	150,000
2023-03-15	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+243K sh	—	—	242,500
2022-07-07	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+162K sh	—	—	161,700
2022-02-04	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+323K sh	—	—	323,400
2022-02-04	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+80.9K sh	—	—	80,850
2020-12-01	ALGSAligos Therapeutics, Inc. · Stock Option (Right to Buy)A Award	Director, President and CEO	AAward	+450K sh	—	—	450,000
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+41K sh	—	—	41,016
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+123K sh	—	—	122,601
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+13.7K sh	—	—	13,671
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+13.7K sh	—	—	13,671
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+50.7K sh	—	—	91,728
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+3,394 sh	—	—	17,065
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+3,394 sh	—	—	17,065
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+21.7K sh	—	—	113,423
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+1,452 sh	—	—	18,517
2020-10-20	ALGSAligos Therapeutics, Inc.C Conversion	Director, President and CEO	CConversion	+1,452 sh	—	—	18,517
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, President and CEO	CConversion	−41K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, President and CEO	CConversion	−123K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, President and CEO	CConversion	−13.7K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series A Preferred StockC Conversion	Director, President and CEO	CConversion	−13.7K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, President and CEO	CConversion	−50.7K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, President and CEO	CConversion	−3,394 sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-1 Preferred StockC Conversion	Director, President and CEO	CConversion	−3,394 sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-2 Preferred StockC Conversion	Director, President and CEO	CConversion	−21.7K sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-2 Preferred StockC Conversion	Director, President and CEO	CConversion	−1,452 sh	—	—	0
2020-10-20	ALGSAligos Therapeutics, Inc. · Series B-2 Preferred StockC Conversion	Director, President and CEO	CConversion	−1,452 sh	—	—	0
2008-05-19	INTERMUNE INCM Exercise/Conversion	Frmr Chief Scientific Officer	MExercise/Conversion	+18.5K sh	$10.11	+$187K	25,622
2008-05-19	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−18.5K sh	$15.37	−$285K	7,083
2008-05-19	INTERMUNE INCNon-Qualified Stock Option (right to buy)M Exercise/Conversion	Frmr Chief Scientific Officer	MExercise/Conversion	−18.5K sh	—	—	0
2008-05-16	INTERMUNE INCF Tax Payment	Frmr Chief Scientific Officer	FTax Payment	−376 sh	$15.48	−$5,820.48	7,083
2008-01-02	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−3,357 sh	$13.26	−$44.5K	0
2006-08-14	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−500 sh	$16.42	−$8,210	20,941
2006-08-14	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−500 sh	$16.49	−$8,245.45	20,441
2006-08-14	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−400 sh	$16.49	−$6,596	20,041
2006-08-14	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−200 sh	$16.47	−$3,294	19,841
2006-08-14	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−300 sh	$16.45	−$4,935	19,541
2006-08-14	INTERMUNE INCS Sale	Frmr Chief Scientific Officer	SSale	−1,398 sh	$16.44	−$23K	18,143

Recent filings

Accepted (ET)
Mar 114
BLATT LAWRENCE0001610717-26-000092
SEC(opens sec.gov)
Jul 184
BLATT LAWRENCE0001610717-25-000290
SEC(opens sec.gov)
Mar 44
BLATT LAWRENCE0001610717-25-000046
SEC(opens sec.gov)
Sep 64
BLATT LAWRENCE0001610717-24-000465
SEC(opens sec.gov)
Mar 44
BLATT LAWRENCE0001610717-24-000121
SEC(opens sec.gov)
Feb 284
BLATT LAWRENCE0001610717-24-000098
SEC(opens sec.gov)
Oct 274
BLATT LAWRENCE0001610717-23-000319
SEC(opens sec.gov)
Sep 124
BLATT LAWRENCE0001610717-23-000273
SEC(opens sec.gov)
Mar 174
BLATT LAWRENCE0001567619-23-005251
SEC(opens sec.gov)
Jul 114
BLATT LAWRENCE0001567619-22-013866
SEC(opens sec.gov)
Feb 84
BLATT LAWRENCE0001567619-22-002892
SEC(opens sec.gov)
Dec 34
BLATT LAWRENCE0001567619-20-020621
SEC(opens sec.gov)
Oct 204
BLATT LAWRENCE0001567619-20-018001
SEC(opens sec.gov)

Companies

Address

C/O ALIGOS THERAPEUTICS, INC. 1 CORPORATE DRIVE, 2ND FLOOR

SOUTH SAN FRANCISCO, CA, 94080